Who Paid My Doc
Majd Ibrahim
Cardiovascular Disease Salt Lake Cty, UT Medical Doctor
NPI 1700199627 CMS profile 1038327
50 W Broadway Ste 300, Salt Lake Cty, UT 84101
General payments
$2,739
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$64,509
Through program year 2025, Majd Ibrahim of Salt Lake Cty, UT is reported in the CMS Open Payments database as having received $2,739 across 22 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $64,509 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 56th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $83 | 2 | |
| 2024 | General | $644 | 7 | |
| 2023 | General | $332 | 3 | |
| 2022 | General | $98 | 1 | |
| 2019 | General | $1,583 | 9 |
Beside peers
- Majd Ibrahim
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Majd Ibrahim were reported at $83. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Majd Ibrahim | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,583 | $450 | $127–$1,392 | $163 |
| 2020 | $0 | $242 | $77–$751 | $114 |
| 2021 | $0 | $335 | $101–$1,037 | $132 |
| 2022 | $98 | $395 | $121–$1,211 | $149 |
| 2023 | $332 | $443 | $136–$1,283 | $160 |
| 2024 | $644 | $450 | $136–$1,323 | $164 |
| 2025 | $83 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$22,739
Medicare patients
211
Services billed
836
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 61% | |
| Heart failure | 47% | |
| Arthritis | 43% | |
| Atrial fibrillation | 37% | |
| Diabetes | 30% | |
| Chronic kidney disease | 30% | |
| Depression | 28% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadoteridol, (prohance multipack), per ml A9576 | Office | 18 | 240 | $280 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ZENPEP |
|
$472 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
22 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Utah
John Ryan
Cardiovascular Disease · Salt Lake City, UT
Robert Fowles
Cardiovascular Disease · Salt Lake City, UT
Brian Whisenant
Cardiovascular Disease · Murray, UT
Andrew Behunin
Cardiovascular Disease · Draper, UT
Jeffrey Osborn
Cardiovascular Disease · Salt Lake City, UT
James Fang
Cardiovascular Disease · Salt Lake City, UT
Related records
Cardiovascular Disease in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.